Progestogel is a gel containing the hormone progesterone, used as a topical product. Its core therapeutic use is for the relief of breast-related pain and discomfort, generally applied across domains where additional symptomatic support is needed.

---

Supportive Care for Physical Discomfort

The medication is commonly used to help with symptoms related to physical discomfort, such as painful pressure or tenderness in the breasts (mastodynia). The gel supports the patient during difficult episodes by easing distress and contributing to improved day-to-day comfort. It is relevant in clinical settings marked by increased discomfort or tension.

---

Managing Episodic Manifestations

Progestogel is applicable when short-term symptomatic assistance is needed during phases where the patient experiences heightened discomfort. It helps address symptom clusters that may become intense or disruptive, assisting with maintaining functional stability when symptoms become more noticeable. This supportive relief contributes to improved comfort during symptomatic periods and is used in situations involving recurrent or episodic manifestations like benign breast pathologies (mastopathies).

Quick Fact: Focus on Symptom Fluctuation The gel is relevant in contexts involving symptoms associated with acute or episodic changes, often used when symptoms may intensify temporarily.

Who Can and Cannot Use Прожестожель? (Official Regulatory Information)

Eligibility Scope

The eligibility profile for Прожестожель (topical progesterone gel) is strictly defined by regulatory authorities and focuses on specific patient populations and medical conditions. Use is permitted only for adult women diagnosed with conditions such as painful pressure in the breasts (mastodynia) or associated with benign cystic pathologies of the breasts (mastopathies).

Contraindications and Restrictions

Contraindicated Populations are those who must not use the medicine under any circumstances, including patients with a known hypersensitivity to the active substance (Progesterone) or its excipients. The medicine is also strictly contraindicated during pregnancy.

Use is prohibited for patients with known or suspected malignancy of the breast or genital organs (progesterone-sensitive tumors) and those with undiagnosed vaginal (genital) bleeding. These restrictions are based on the hormonal nature of the medication and high-risk comorbid conditions. The medicine is not prescribed for men.

Age and Lactation Restrictions

The label states that the product should be avoided during breastfeeding (lactation), and it has no relevant use or established safety profile for the pediatric population (children and adolescents).

The regulatory documentation for Прожестожель (Topical Micronized Progesterone Gel) establishes that its official interaction profile is defined by the absence of documented drug and substance interactions. This particular status is a reflection of the product's formulation for localized use, resulting in minimal systemic absorption that is generally insufficient to trigger clinically significant pharmacokinetic or pharmacodynamic interactions.

Drug-Drug Interactions

Regulatory authorities have not documented any known or expected interactions between the topical gel formulation and other medicinal products. The official Summary of Product Characteristics (SmPC) states that formal interaction studies have not been conducted for this specific product, and consequently, no drug interaction exists to date. This is consistent across all major regulatory classifications, meaning no substances are formally listed as contraindicated for co-administration based on interaction risk. Furthermore, the labeling does not include any mandatory rules requiring the spacing or timing separation of doses from other medications.

Interactions with Food, Alcohol, and Supplements

The official patient information notices confirm that there are no documented interaction restrictions involving food, alcohol, herbal products, or supplements. Interactions with food and drink are explicitly listed as Not Applicable for this external-use preparation. The profile also contains no specific cautions regarding heightened interaction risks for any particular population, such as individuals with hepatic or renal impairment. This regulatory structure is the sole source of official interaction information for the product.

Molecular Mechanism and Local Physiological Action

Прожестожель (Progestogel) is a topical progesterone preparation. Following dermal application, it delivers progesterone to target tissues, resulting in high local concentrations. Once absorbed, progesterone interacts with specific intracellular progesterone receptors in the epithelial cells of the mammary glands. This interaction modulates estrogen receptor expression, which leads to the inhibition of estrogen-induced cellular proliferation.

Progesterone’s receptor binding also modulates factors affecting capillary wall permeability, leading to an altered fluid exchange dynamics in the extracellular space of the glandular tissue. Furthermore, it modulates trophic factor expression and decreases the expression of prolactin receptors, thereby reducing the downstream signaling potential of prolactin in mammary tissue. This combination of intracellular actions describes the drug's mechanism at the molecular and localized physiological level.

Прожестожель (Progestogel) is administered exclusively via the topical (cutaneous) route and is for external use only. The standard dose is a specific amount of gel, precisely measured using a graduated measure or spatula supplied with the product. This single measure, which contains 2.5 g of the gel, delivers 25 mg of the active ingredient, progesterone.

Standard application is once daily. The timing may follow a specific pattern, typically administered in a cyclic manner from the 10^th to the 25^th day of the menstrual cycle, although continuous daily use may also be followed. The gel must be applied to clean, dry, and unbroken skin and gently massaged into both breasts until fully absorbed; hands should be washed thoroughly after use to prevent product transfer.

For continuous administration, a medical re-evaluation is recommended after three months of use to confirm the suitability of the ongoing regimen. Furthermore, the product is prohibited for use in children and adolescents under 18 years of age and is not indicated for men. If a dose is forgotten, the standard procedure is to continue with the next scheduled dose and not compensate by applying a double quantity.

Usage Instruction	Standard Condition
Route of Administration	Topical (Cutaneous) use only.
Standard Dose	One graduated measure (2.5 g gel) once daily.
Application Area	Applied to both breasts.
Age Restriction	Use is prohibited in patients under 18 years.

These instructions define the standardized approach to using the medicine.

Evidence for Topical Progesterone Gel

Research on the use of topical progesterone gel (such as Прожестожель) has largely concentrated on mastalgia (breast pain) and fibrocystic breast disease.

Studies have investigated the potential for local application to influence hormone levels within the breast tissue itself, rather than producing high systemic concentrations throughout the body.

Research Focus	Key Findings from Studies
Mastalgia & Pain	Multiple studies observed an association between the use of topical progesterone gel and a significant decrease in self-reported breast pain (mastalgia) and tension (mastodynia) scores, often within a few months.
Fibrocystic Changes	Research explored whether the application of the gel might be associated with a reduction in the size and number of benign breast cysts in women diagnosed with fibrocystic breast changes.
Tissue-Level Effects	Experimental and short-term trials suggested that topical progesterone application may be associated with a decrease in the mitotic activity (cell division) of mammary epithelial cells, potentially balancing the effects of estrogen in the tissue.

---

Safety and Duration of Research

A large French cohort study involving women with benign breast disease who used percutaneous progesterone (a similar topical administration) found no association with an increased risk of breast cancer over a follow-up period. The evidence remains limited regarding the long-term effects of continuous use extending beyond two years. The gel's safety profile is generally considered favorable in the studied populations, with few major adverse events reported in clinical trials.

Key Studies & References

1. Impact of topical progesterone gel on fibrocystic breast disease: clinical and radiological findings

Common questions about Прожестожель (FAQ)

Q: Can Прожестожель be used by women who have not gone through menopause?

According to the official product information, the drug is permitted for use by adult women who have been diagnosed with conditions such as painful breast pressure (mastodynia) or benign cystic changes in the breast (mastopathies). The eligibility criteria focus on these specific medical conditions rather than a patient's menopausal status.

Q: How quickly does Прожестожель start working after the first application?

Studies focusing on therapeutic effects have noted that a significant decrease in reported breast pain and tension scores is often observed within a few months of starting treatment. This observation relates to the onset of the expected therapeutic outcome.

Q: Is there a risk of developing skin irritation from the gel?

Regulatory documentation advises that patients must be monitored for signs of hypersensitivity reactions, which include localized effects such as skin irritation or redness at the application site. These reactions are included in the official safety profile.

Q: Do any foods or supplements need to be avoided while using Прожестожель?

Official patient information confirms that for this topical external-use preparation, there are no documented interaction restrictions involving food, alcohol, herbal products, or dietary supplements. Interactions with these substances are explicitly listed as Not Applicable.

Q: Is it necessary to use Прожестожель at a specific time of day?

Official instructions require application once daily. The official guidance describes use either in a cyclic pattern (e.g., from day 10 to day 25 of the menstrual cycle) or as continuous daily use, but does not strictly specify the time of day.

Q: Does the body absorb Прожестожель through the skin effectively?

The topical gel formulation is designed to deliver progesterone to the target tissues in a focused way. This action results in high local concentrations of the hormone in the applied area. This delivery mechanism is considered distinct from the effects of systemic hormonal medications.

Q: Has Прожестожель been studied in women with other chronic health conditions?

The research evidence summary focuses heavily on the use of the topical gel for conditions like mastalgia (breast pain) and fibrocystic breast disease. Official documentation provided does not detail studies regarding its use in women with other chronic health conditions.

Q: Is Прожестожель safe for women who are breastfeeding?

The official label states that the product should be avoided during breastfeeding (lactation).

Q: Does Прожестожель interact with common pain relievers like ibuprofen or aspirin?

Regulatory authorities have not documented any known or expected interactions between the topical gel formulation and other medicinal products, which includes common over-the-counter pain relievers. The official SmPC states that no drug interaction exists to date.

Q: Why do doctors prescribe Прожестожель for mastopathy?

The rationale for use is rooted in the drug's local mechanism of action. The progesterone is described as modulating factors that affect estrogen receptor expression and cellular proliferation in the breast tissue. This action helps to modulate fluid exchange dynamics in the glandular tissue, which are often implicated in mastopathy symptoms.

Q: How long does the effect of one application of Прожестожель last?

The official instructions require application once daily. This consistent dosing schedule implies that the intended therapeutic coverage provided by the medication is typically aligned with a 24-hour period.

Q: What are the general expectations for the duration of treatment with Прожестожель?

For continuous administration, official guidelines recommend a medical re-evaluation after three months of use. This check is performed to confirm the ongoing suitability of the regimen.

Q: Is Прожестожель known to interact with blood pressure or heart medications?

Regulatory authorities have not documented any known or expected interactions between the topical gel formulation and other medicinal products, which includes blood pressure or heart medications. The official SmPC states that no drug interaction exists to date.

Q: Is Прожестожель available over the counter in some countries?

The preparation is officially designated for prescription use (Rx status). This regulatory designation indicates that the medicine typically requires a prescription from a healthcare provider.

Q: Can Прожестожель affect the results of blood tests?

The drug is formulated for localized effect and minimal systemic absorption. Due to this distinction, the product is generally considered different from systemic hormonal medications in terms of risk of interference with standard blood test results.

Q: Is it possible to have an allergic reaction to ingredients in Прожестожель?

Yes, regulatory information indicates that hypersensitivity and allergic reactions are possible. Use is strictly prohibited (contraindicated) for individuals with a known hypersensitivity or allergy to progesterone or any gel components. Rare allergic reactions are listed as a category of adverse reactions.

Q: Can Прожестожель be used together with hormone replacement therapy (HRT)?

The regulatory documentation confirms that there are no known or expected interactions between the topical gel formulation and other medicinal products, which includes the components of Hormone Replacement Therapy. The official Summary of Product Characteristics states that no drug interaction exists to date.

Q: Is there a recommended maximum duration for using Прожестожель?

While there is no fixed maximum duration defined, official guidelines recommend a medical re-evaluation after three months of continuous use. This periodic check is intended to confirm the ongoing suitability of the treatment regimen.

Q: Are there any studies comparing the topical application site's effect on absorption?

Official instructions require the application of the gel to both breasts. However, the provided summary of research evidence does not contain information on studies comparing the effect of different topical application sites on the drug's absorption.

Q: Is Прожестожель known to interact with alcohol consumption?

Official patient information confirms that there are no documented interaction restrictions involving food, alcohol, herbal products, or supplements. The interaction profile for this external-use preparation indicates no official restriction on alcohol consumption.

Q: Is Прожестожель meant to be a permanent or temporary treatment?

Official instructions describe use either in a cyclic manner (following the menstrual cycle) or as continuous daily use. The requirement for a medical re-evaluation after three months suggests the regimen is subject to regular review and is not automatically considered permanent.

Q: Can people with liver or kidney issues use Прожестожель?

The use of progesterone is generally contraindicated in cases of severe hepatic impairment (severe liver failure). The regulatory structure, however, does not contain specific cautions regarding heightened interaction risks for the general population with less severe hepatic or renal impairment.

Q: Why do some people experience localized swelling with Прожестожель?

The drug's mechanism of action is described as modulating factors that affect capillary wall permeability in the glandular tissue. This action can lead to an altered fluid exchange dynamics in the extracellular space, which is the physiological mechanism related to localized swelling.

Q: Can Progestogel be used to manage PMS symptoms?

The official eligibility profile strictly defines the medicine's use for adult women diagnosed with specific breast conditions: painful pressure in the breasts (mastodynia) or benign cystic pathologies of the breasts (mastopathies). It is not indicated for the general management of Pre-Menstrual Syndrome (PMS) symptoms.

Q: Are there any known interactions between Прожестожель and thyroid medications?

Regulatory authorities have not documented any known or expected interactions between the topical gel formulation and other medicinal products, which includes thyroid medications. The official SmPC states that no drug interaction exists to date.

Q: What should be done if the area of application feels unusually warm or red?

Regulatory documentation emphasizes that patients must be monitored for signs of hypersensitivity reactions, such as skin irritation or redness at the application site. Official guidance indicates that should any systemic effects occur, the medicine is typically discontinued.

Q: Does Прожестожель have any known interactions with hormonal birth control?

Regulatory authorities have not documented any known or expected interactions between the topical gel formulation and other medicinal products, which includes hormonal birth control. The official SmPC states that no drug interaction exists to date.

The storage and disposal of Прожестожель (Progestogel) must strictly adhere to the requirements defined in official regulatory labeling to ensure product stability and safety.

Storage Conditions

• Temperature: Store the gel at controlled room temperature, specifically not exceeding 25 C (77 F) [Source: ANSM]. Storage above this maximum temperature or exposure to excessive heat must be avoided.
• Handling Protection: The product must be protected from freezing and excess moisture to maintain its gel integrity [Source: NIH/MedlinePlus].
• Packaging: Keep the medicine in the original container and ensure the cap is tightly closed [Source: NIH/MedlinePlus].
• Child Safety: All medication must be kept out of the sight and reach of children [Source: ANSM; NIH].

Disposal Instructions

Do not dispose of unused or expired Прожестожель in household waste or by flushing it into the sewerage system (wastewater) [Source: ANSM]. To comply with environmental protection rules, unused product should be returned to a pharmacist or a designated collection point for appropriate pharmaceutical waste handling.